News

PHEXCOM

Solution BY Communication

Call：+86 021-55807300

Position：Home > News >

Patent loss on MS hit Tecfidera puts pressure on Biogen to score a win in Alzheimer's: analysts

Now that the worst-case scenario for Biogen in its Tecfidera patent battle with Mylan has come to pass, Wall Street analysts have a warning for investors: New generic competition to the multiple scle
2020/6/22
Novavax, advancing COVID-19 shot, recruits AstraZeneca exec as its chief medical officer

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief m
2020/6/19
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Novartis and Eli Lilly have been jockeying for new indications and commercial success for their IL-17 inhibitors Cosentyx and Taltz, respectively. Lilly appeared to get the label-expansion edge with
2020/6/19
U.K. endorses dexamethasone in COVID-19 hours after groundbreaking data release

Right on the heels of data showingthe decades-old, inexpensive steroid dexamethasone can reduce COVID-19 deaths among hospitalizedpatients requiring oxygen, the U.K. government granteda world-first a
2020/6/18
Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers

Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help
2020/6/18
AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function

AstraZeneca’s Farxiga is already getting a speedy FDA review as a treatment for chronic kidney disease (CKD), but it’s still piling on the positive results. A new analysis of the company’s Declare-Ti
2020/6/17
FDA yanks chloroquine's emergency OK after data show it doesn't work against COVID-19

It's been more than 2 months since President Donald Trump touted malaria drugs as a possible "game-changer" for coronavirus treatment, and the FDA quickly signed off on their emergency use during the
2020/6/17
Eli Lilly, spurred by AI analysis, starts pivotal study of arthritis med Olumiant in COVID-19

As drugmakers mobilize to repurpose existing medicines for COVID-19, Eli Lilly is hoping its arthritis med Olumiant could play a part. The Indianapolis pharma haskicked offa phase 3 clinical trial te
2020/6/16
AstraZeneca spinoff Viela Bio scored its first FDA nod. Can it face down heavyweight rivals?

Two years after launching, AstraZeneca spinoffVielaBio has its first FDA approval inUplizna following Friday'snodto treat certainpatients with neuromyelitisopticaspectrum disorder. Analysts expect th
2020/6/16
Net prices decline in the first quarter, but the political threat returns

With the U.S. presidential race and Senate contests getting into high gear, one prominent biopharma analyst sees warning signs for the industry. Meanwhile, net prices fell in the first quarter, and t
2020/6/15

Excipients